與中國(guó)建立對(duì)話(huà)橋梁

文/Thomas Tursz 譯/李藝雯

與中國(guó)建立對(duì)話(huà)橋梁

To Establish Fruitful Links and Dialogues with China

文/Thomas Tursz 譯/李藝雯

法國(guó)古斯塔夫研究所教授、名譽(yù)所長(zhǎng)Thomas Tursz博士在世界癌癥大會(huì)開(kāi)幕式上演講

作為一個(gè)已經(jīng)十三四次造訪(fǎng)中國(guó)的西方學(xué)者，無(wú)論是人文視野，還是學(xué)術(shù)方面，我的每次經(jīng)歷都是令人炫目的，充滿(mǎn)驚奇又富有啟示性。

For a Westerner like me, who is now visiting China for the 13th or 14 th time, every visit is a dazzling, astonishing and instructive experience, both on the scientific and the human sights.

我1987年第一次來(lái)到中國(guó)，令我今日頗為感慨的是當(dāng)年邀請(qǐng)我來(lái)華的中國(guó)頂尖科學(xué)家，正是今天和我一同擔(dān)任本屆世界癌癥大會(huì)榮譽(yù)主席的曾毅教授。

My first visit in China was in 1987. I am really quite moved today to remind that the Chinese leading scientist who invited me here for this first visit was Professor Zeng Yi, who is today the Honorary Chairman of this WCC 2015 Conference together with me.

1987年，我和曾毅教授對(duì)中國(guó)南部地區(qū)，具有地方性的，伴隨EB病毒感染的鼻咽癌，都很感

In 1987, Prof. Zeng Yi and I were both interested in naso-pharyngeal carcinomas (NPC), endemic in Southern China, and associated with the Epstein-Barr virus (EBV). Yi was conducting extraordinary and pioneer興趣。曾教授在南方所指導(dǎo)的使用抗EB病毒血清進(jìn)行鼻咽癌早期診斷的研究在當(dāng)時(shí)是非常前衛(wèi)而非凡的工作。得益于他，我能拜訪(fǎng)他在北京的研究所，以及位于廣西南寧城郊的鼻咽癌研究現(xiàn)場(chǎng)。works on early diagnosis of NPC in Southern China, using anti-EBV serology. Thanks to him, I could visit his own Institute in Beijing, and the NPC fields in the countryside around Nanning, in the Guang-Xi region.

1987年以來(lái)，我到訪(fǎng)過(guò)很多中國(guó)的研究所并親眼見(jiàn)證眾多獨(dú)特非凡的研究成果，每一個(gè)都可謂學(xué)術(shù)領(lǐng)域的重大突破。

1987年的中國(guó)，大多數(shù)實(shí)驗(yàn)室只有一個(gè)離心分離機(jī)和一個(gè)顯微鏡?，F(xiàn)如今，生命科學(xué)的最新科技，如DNA高通量測(cè)序，已經(jīng)逐漸普及到每個(gè)研究機(jī)構(gòu)。高精尖的科研人員與醫(yī)生層出不窮。在癌癥患者的日常護(hù)理方面的進(jìn)步也屬全球領(lǐng)先。

Since 1987, I have visited many Institutes in China and could see with my own eyes the extraordinary and unique progresses, which are actually scientifical giant steps.

In 1987, very few labs were equipped with more than one centrifuge and one microscope. Now, almost everywhere, the most recent technologies in life sciences, like next generation DNA sequencing (NGS) are available and growing everyday. The number of well educated and highly competent scientists and physicians is unbelievable to us, and the quality of care daily provided to cancer patients have improved as nowhere else in the world.

我不確信西方的大多數(shù)從未到訪(fǎng)中國(guó)的學(xué)者能夠充分意識(shí)和領(lǐng)悟到這些變化的重要現(xiàn)實(shí)意義。

這個(gè)時(shí)代，當(dāng)新技術(shù)、新靶向藥物、新疾病分類(lèi)都可以迅速影響全球癌癥治療，并在概念、思維方式及現(xiàn)代腫瘤學(xué)臨床工具上取得實(shí)質(zhì)性的革命，我非常相信，中國(guó)將在這場(chǎng)影響深遠(yuǎn)的變革中扮演關(guān)鍵的、革新性的角色。與中國(guó)團(tuán)隊(duì)或機(jī)構(gòu)的合作，將不再被認(rèn)為是“如何幫助發(fā)展中國(guó)家”或者“來(lái)訓(xùn)練西方最優(yōu)秀人才”，而是如何與這位新晉醫(yī)學(xué)和科學(xué)巨人構(gòu)建富有成效的對(duì)話(huà)橋梁，并且不久，這種合作將轉(zhuǎn)變?yōu)榭茖W(xué)研究上的必要需求。（摘編自Thomas Tursz博士5月15日在世界癌癥大會(huì)開(kāi)幕式上的演講）

I am not sure that most Western scientists, who have never visited China, are fully aware and realizing the practical importance of these major changes.

At a time when new technologies, new targeted agents, and new disease classifications will soon dramatically impact global cancer care, and will achieve a true Revolution in the concepts, the way of thinking and the practical tools of modern Oncology, I am firmly convinced that China will play a crucial and innovative role in these seminal changes. Collaborating with Chinese groups or Institutes will no longer be regarded as ‘how to help a developing country’ or ‘to train the best people in the West’, but how to establish fruitful links and dialogues with this new medical and scientific giant, and will soon appear as a mandatory scientific necessity.

(From the speech of Mr. Thomas Tursz on the opening ceremony of 8th Annual World Cancer Congress)

德國(guó)腫瘤學(xué)專(zhuān)家Reiner C. Hartenstein教授（左一）與阜陽(yáng)市第二人民醫(yī)院專(zhuān)家共同會(huì)診